---
figid: PMC11539471__40364_2024_679_Fig2_HTML
figtitle: Mechanisms of action of clinically studied CAR-T targets in gliomas
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC11539471
filename: 40364_2024_679_Fig2_HTML.jpg
figlink: /pmc/articles/PMC11539471/figure/F2/
number: F2
caption: The mechanisms of action of clinically studied CAR-T targets in gliomas.
  EGFRvIII promotes GBM development mainly by enhancing the EGFRvIII-PI3K-AKT signalling
  pathway, EGFRvIII-Ras-Raf-MEK-ERK/MAPK signalling pathway and EGFRvIII-JAK-STAT
  signalling pathway; IL-13Rα2 competitively binds to IL-13, thereby inhibiting the
  STAT6 signaling pathway, promoting tumor cell invasion, metastasis, and proliferation,
  and inhibiting tumor cell apoptosis; Tumor formation via MAPK/ERK and PI3K/AKT/mTOR
  signalling pathways when HER2 gene expression is aberrant or GD2 is expressed; B7H3
  enhanced cancer cell invasion by regulating the JAK2/STAT3 signalling pathway and
  upregulated the expression of vascular endothelial growth factor A (VEGFA) to promote
  tumor angiogenesis; Overexpressed EphA2 promotes tumor progression through AKT/RSK/PKA-mediated
  phosphorylation events
papertitle: Advances in CAR-T therapy for central nervous system tumors
reftext: Delian Zhou, et al. Biomark Res. 2024;12(NA).
year: '2024'
doi: 10.1186/s40364-024-00679-6
journal_title: Biomarker Research
journal_nlm_ta: Biomark Res
publisher_name: BMC
keywords: Central nervous system tumors | Chimeric antigen receptor T-cell therapy
  | Glioblastoma | Medulloblastoma | Central nervous system lymphoma | Central nervous
  system acute lymphoblastic leukemia | Brain tumors
automl_pathway: 0.9330181
figid_alias: PMC11539471__F2
figtype: Figure
redirect_from: /figures/PMC11539471__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11539471__40364_2024_679_Fig2_HTML.html
  '@type': Dataset
  description: The mechanisms of action of clinically studied CAR-T targets in gliomas.
    EGFRvIII promotes GBM development mainly by enhancing the EGFRvIII-PI3K-AKT signalling
    pathway, EGFRvIII-Ras-Raf-MEK-ERK/MAPK signalling pathway and EGFRvIII-JAK-STAT
    signalling pathway; IL-13Rα2 competitively binds to IL-13, thereby inhibiting
    the STAT6 signaling pathway, promoting tumor cell invasion, metastasis, and proliferation,
    and inhibiting tumor cell apoptosis; Tumor formation via MAPK/ERK and PI3K/AKT/mTOR
    signalling pathways when HER2 gene expression is aberrant or GD2 is expressed;
    B7H3 enhanced cancer cell invasion by regulating the JAK2/STAT3 signalling pathway
    and upregulated the expression of vascular endothelial growth factor A (VEGFA)
    to promote tumor angiogenesis; Overexpressed EphA2 promotes tumor progression
    through AKT/RSK/PKA-mediated phosphorylation events
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - il13
  - epha2a
  - epha2b
  - her1
  - her3
  - her4.1
  - il4r.1
  - her2
  - egfra
  - il13ra2
  - rab1ab
  - jak2b
  - vegfaa
  - stat6
  - stat3
  - stat1b
  - stat4
  - mtor
  - IL13
  - CD276
  - EPHA2
  - EGFR
  - ERBB3
  - ERBB4
  - IL4R
  - ERBB2
  - IL13RA2
  - KRAS
  - HRAS
  - NRAS
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - VEGFA
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - RPS6KB1
  - RPS6KB2
  - STAT6
  - STAT3
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - SOAT1
  - STAT1
  - STAT2
  - STAT4
  - STAT5A
  - STAT5B
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - RAS
  - MEK
---
